Arena Looking To Puff Up Belviq Sales With Smoking Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Arena’s Belviq has failed to gain much traction in the obesity market, but the biotech is hoping a smoking-cessation indication could help bolster sales.
You may also be interested in...
Obesity Market Snapshot: Competition Is Good For Everyone, Especially Orexigen
With more than two years of competition behind them, it’s becoming clear that latecomer Contrave might just be the star of the obesity drug market, while its competitors are stuck playing second fiddle. Yet, all players are benefiting from increased obesity sales reps in the field.
Liraglutide’s FDA Panel For Weight Loss Is Test Of Diabetes Experience
Novo looks to expand indication for its popular diabetes drug, which if approved would go up against competitors that have had trouble on the market.
Contrave Launch Strategy: Comfortable Drug To Combat Effects Of Comfort Food
Orexigen and marketing partner Takeda’s efforts “will be scaled like a typical diabetes launch,” making it much larger than other recent obesity launches.